23andMe Judge Questions Limits for New Auction for Bankrupt Firm

In the 23andMe bankruptcy case, Judge Brian Walsh has raised concerns about proposed limits for a second auction intended to solicit bids exceeding Regeneron Pharmaceuticals' current $256 million offer. The judge is pressing lawyers for Regeneron and 23andMe to justify these limits, which have drawn criticism from a competing bidder, a research institute supported by former CEO Anne Wojcicki, potentially impacting the final valuation and control of the genetic-testing firm.

Analysis

The bankruptcy proceedings of genetic-testing firm 23andMe are encountering judicial scrutiny over the proposed framework for a second auction. US Bankruptcy Judge Brian Walsh has specifically questioned the limits designed to elicit bids exceeding Regeneron Pharmaceuticals' (REGN) current $256 million offer. These proposed auction limits, which are supported by Regeneron and 23andMe, have drawn criticism from the only other declared bidder, a California-based research institute notably backed by 23andMe's former Chief Executive Officer, Anne Wojcicki. This intervention by the judge, coupled with active opposition from a rival bidder, introduces significant uncertainty into the auction dynamics. The resolution of this dispute over auction parameters could materially impact the final sale price for 23andMe's assets and the ultimate control of the company, directly influencing Regeneron's strategic acquisition attempt and potentially fostering a more competitive bidding landscape.

Key Decisions for Investors

• Investors in Regeneron (REGN) should closely monitor the developments in 23andMe's bankruptcy auction, as the judicial review of auction limits could foster a more competitive bidding process, potentially requiring Regeneron to increase its $256 million offer to secure the assets.
• The challenge to the auction limits by a rival bidder connected to 23andMe's former CEO signals a determined effort to achieve a higher valuation, which may prolong the auction or compel Regeneron to reassess its bidding strategy and financial commitment.
• Given the signaled low market impact and neutral per-ticker sentiment for REGN, the immediate stock price effect may be muted, but a significant escalation in the final acquisition price for 23andMe could impact Regeneron's capital allocation and should be considered in assessing REGN's near-term financial outlook if the deal proceeds at a substantially higher cost.